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Abstract Here we show that human protein kinase C W (PKCW)
activates the mitogen-activated protein kinase (MAPK). Tran-
sient expression of constitutive active PKCW leads to an
activation of Raf-1 kinase as demonstrated by in vitro
phosphorylation of MAPK. PKCW enhances transcriptional
activity of a basal thymidine kinase promotor containing serum
response elements (SREs) as shown by luciferase reporter gene
assays. SRE driven gene activation by PKCW is triggered by the
Elk-1 ternary complex factor. PKCW-mediated activation of
SRE driven transcription can be inhibited by the MEK1 inhibitor
PD98059. In contrast to the activation of the p42/ERK1 MAPK
cascade, transient expression of constitutive active PKCW does
neither affect c-jun N-terminal kinase nor p38 MAPK. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The protein kinases C (PKCs) comprise a family of intra-
cellular serine/threonine speci¢c kinases, that are implicated in
signal transduction of a wide range of biological responses
including changes in cell morphology, proliferation and di¡er-
entiation [1^3]. The 13 members of the family can be grouped
into three major classes of Ca2-dependent classical PKCs
(cPKCs), Ca2-independent, novel PKCs (nPKCs), and
Ca2- and lipid-independent atypical PKCs (aPKC). The
fourth PKC subgroup consisting of PKCW [4], its mouse ho-
mologue PKD [5], PKCX [6] and PKD2 [7] share common
structures like amino-terminal cysteine ¢ngers de¢ning the
structural basis for lipid-mediated activation. They di¡er
from the three major groups of PKC isozymes by the presence
of an acidic domain [8], a pleckstrin homology (PH) domain
[9] and the lack of a typical pseudosubstrate site. PKCW/PKD
is ubiquitously expressed and involved in diverse cellular func-
tions like constitutive transport processes in epithelial cells
[10], G protein-mediated regulation of Golgi organization
[11] and protection from apoptosis [12].
PKCW/PKD is activated by the growth factor PDGF [13]
via a PLCQ-mediated pathway [14] pointing to a role in the
extracellular signal-regulated kinase/mitogen-activated protein
kinase (ERK/MAPK) cascade. The MAPK cascade, which
involves the kinases Raf-1, MAPK/ERK kinase (MEK) and
ERK/MAPK [15], is ubiquitously expressed in mammalian
cells and serves to couple various cell surface stimuli to the
alteration of cell function. This cascade is implicated in both
regulation of cell proliferation as well as in the control of
di¡erentiation. Such actions are elicited at least in part
through the translocation of activated MAPK to the nucleus,
where it phosphorylates target molecules such as the tran-
scription factors Elk-1 and SAP1, which consequently leads
to alterations in gene expression [16]. Evidence for the in-
volvement of PKCs in MAPK activation comes from the ac-
tion of the tumor promotor phorbol ester leading to a rapid
activation in most cell types [17]. Since PKC is the major
receptor for phorbol ester, it has been implicated in the acti-
vation of the ERK/MAPK pathway and the triggering of
cellular responses such as cell di¡erentiation and proliferation.
Further work proofed that c- and nPKC isotypes activate the
MAPK pathway on the level of Raf-1 whereas aPKCs acti-
vate MEK by an independent mechanism [18,19]. As PKCW/
PKD is activated directly by lipids [20] and by PDGF [13]
similarly as other PKCs, we analyzed its function in signaling
pathways leading to transcription factor activation via the
MAPKs.
In this study we demonstrate that PKCW selectively acti-
vates the ERK1/2 MAPK cascade at the level of Raf-1 kinase
leading to p42 MAPK activation, which results in enhanced
Elk-1-mediated transcription of serum response element
(SRE) driven reporter genes.
2. Materials and methods
2.1. PKCW expression plasmids and antibodies
The cloning of the PKCW expression constructs used has been de-
scribed previously [12,21]. PKCW was detected with a rabbit antibody
D20 (Santa Cruz). Secondary alkaline phosphatase-linked goat anti-
mouse IgG and goat anti-rabbit IgG antibodies were purchased from
Dianova or Sigma. Protease inhibitors and phosphatases were from
Biomol. Phorbol ester (phorbol 12,13-dibutyrate, PdBu) was pur-
chased from Sigma. HEK293 cells (ATCC) were cultured in RPMI
medium supplemented with 5% fetal calf serum.
2.2. Raf-1 and p42 activation assay
Raf-1 kinase activity was measured as previously published [22]. In
brief Raf-1 was immunoprecipitated and incubated with 50 ng of ki-
nase competent MEK1 and 150 ng of kinase negative MAPK (ERK1,
Upstate Biotechnology). Phosphorylation was started by adjusting to
2 WM ATP and 5 WCi [Q-32P]ATP. The reaction was incubated for 30
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min at 25‡C and terminated by adding sodium dodecyl sulfate (SDS)
sample bu¡er. Samples were fractionated on a 12.5% SDS^PAGE,
transferred to a nitrocellulose membrane and subjected to overnight
autoradiography and phosphoimaging. p42/44 and p38 activity was
estimated by measuring phosphorylation using phospho-p42/44 and
phospho-p38 speci¢c antibodies (New England Biolabs) according to
the manufacturer’s instructions. Lysates of 3U105 HEK293 cells per
lane were analyzed by Western blot detection. Activation of c-jun N-
terminal kinase (JNK) was measured as described previously [23] us-
ing GST-jun (glutathione S-transferase) fusion proteins as a substrate.
Expression of PKCW and PKCW mutants was veri¢ed in all cases by
Western blot detection.
2.3. Transfections and luciferase reporter gene assays
2U104 HEK293 cells per well (96 well plate) were transfected with
1 Wl Superfect (Qiagen) for 2 h. 50 ng of a L-galactosidase reporter gene
construct (pCH110, Amersham-Pharmacia), 50 ng of a 4USRE-Tk-
luciferase reporter construct and 150 ng of PKCW/pCDNA3 expres-
sion constructs or the respective amount of vector DNA were used.
For inhibition of MAPK activity cells were preincubated for 1 h with
the MEK1 inhibitor PD98059 (40 WM). 48 h after transfection cells
were stimulated with 100 nM phorbol ester for 6 h and harvested in
50 Wl lysis solution (Galacto-light, TROPIX). Lysates were analyzed
for ¢re£y luciferase expression (20 Wl, Promega) and for L-galactosi-
dase expression (10 Wl) using a Lucy2 luminometer (Anthos). Normal-
ized transfection e⁄ciencies are indicated by the quotient of relative
luciferase units and relative L-galactosidase units. All luciferase re-
porter gene assays were carried out in triplicates and were performed
3^5 times. Gene transcription was measured using a 4USRE-Tk-lu-
ciferase or a Tk-luciferase construct [24]. To measure Elk-1-mediated
gene activation pGAL4-luc and pGAL4DB-Elk-1 were used. All re-
porter gene constructs used were gifts of Hans van Dam, Leiden
University, The Netherlands and Bernd Baumann, University of
Ulm, Germany. Transient expression of PKCW in HEK293 cells was
carried out in 6 well plates as previously described [21]. Expression
levels of PKCW were veri¢ed by Western blot analysis.
3. Results and discussion
3.1. PKCW activates Raf-1
PKD, the murine homologue of PKCW, has been reported
to be activated by the growth factor PDGF and several neuro-
peptides via a PKC-mediated pathway [13,25]. This prompted
us to analyze in detail the function of PKCW in growth factor-
related signaling pathways leading to signal ampli¢cation of
mitogenic factors via MAPK cascades. Therefore, HEK293
cells were transfected with constitutive active PKCW. Deletion
of the PH domain of PKD and PKCW (PKCWvPH) has been
demonstrated to constitutive activate the kinase activity [26]
(see Fig. 2D). As Raf-1 is a key enzyme in transmitting pro-
liferative, developmental and oncogenic responses from
growth factors via the MAPK pathway [27^29], we ¢rst ana-
lyzed potential activation of Raf-1 kinase by PKCW. Raf-1
activation was monitored in a coupled kinase assay (Fig. 1):
Raf-1 immunoprecipitates from HEK293 cells upon stimula-
tion with EGF were used as a positive control to phosphor-
ylate in vitro kinase competent MEK, which in turn phos-
phorylates MAPK (Fig. 1, left lanes). Raf-1 activation of
vector-transfected control cells was compared to immunopre-
cipitates from cells transfected with the constitutive active
PKCWvPH expression construct [21]. PKCWvPH displays consti-
tutive kinase activity (see Fig. 2D). As shown in Fig. 1 (upper
panel, right lanes) Raf-1 immunoprecipitates from HEK293
cells transiently expressing PKCWvPH (Fig. 1, lower panel)
showed signi¢cant enhancement of MAPK phosphorylation
compared to Raf-1 immunoprecipitates from vector-trans-
fected cells (Fig. 1, upper panel, right lane). Our data point
to PKCW-mediated activation of Raf-1 similarly as reported
for the c- and nPKCs [18,19]. The regulation of Raf-1 appears
to be very complex [30,31] triggered by several mechanisms
including activation by GTP-bound ras, binding of 14-3-3
proteins [32] and activation by PKCK [33]. In contrast to
PKCK, PKCW does not directly phosphorylate Raf-1 (unpub-
lished observations). Furtheron Raf-1 could not be co-immu-
noprecipitated with PKCW (data not shown). Therefore indi-
rect activation via unknown mediators is most likely.
3.2. PKCW selectively activates p42 MAPK
As constitutive active PKCW enhances Raf-1 kinase activity
we analyzed in detail downstream signaling pathways. Activa-
tion of the p42 MAPK which is triggered by Raf-1 can be
demonstrated upon overexpression of constitutive active
PKCW directly by an independent technique. Using antibodies
speci¢c for phospho-Thr202/Tyr204, the activation of p42/p44
MAPK was measured upon PKCW overexpression. As shown
in Fig. 2A activation of p42/p44 kinase is not detectable in
vector-transfected control cells, but enhancement of p42 ac-
tivity can be demonstrated upon phorbol ester stimulation.
Transient expression of PKCW wild-type leads to a weak en-
hancement of p42 and p44 phosphorylation. In contrast how-
ever, upon phorbol ester stimulation a strong enhancement of
p42 and to a lower degree of p44 phosphorylation was detect-
able. Expression of PKCWvPH leads to an enhancement of p42
phosphorylation which was completely inhibited upon incu-
bation with the MEK1 inhibitor PD98059. Expression of ki-
nase dead PKCWK612W did not show any signi¢cant inhibition
of p42 phosphorylation. Expression of p42/p44 (Fig. 2A, low-
er panel) as well as transgene expression were analyzed by
Western blot analysis (see below).
Although PKCW-mediated Raf-1 activation leads via acti-
vation of the p42/p44 MAPK cascade to gene activation (see
Fig. 3), a role of PKCW in activation of p38-MAPK and SAP/
JNK was conceivable. Therefore we analyzed in HEK293 cells
whether PKCW overexpression a¡ects these kinase cascades.
As shown in Fig. 2B neither expression of constitutive active
PKCWvPH nor expression of the kinase dead PKCWK612W mu-
Fig. 1. PKCW activates Raf-1. Raf-1 immunoprecipitates from
HEK293 cells transfected with the indicated expression constructs
were subjected to a coupled kinase assay (see Section 2) to measure
MAPK phosphorylation. As a control Raf-1 immunoprecipitates
from non-stimulated cells were compared to EGF-stimulated
HEK293 cells. Shown is an autoradiograph upon overnight expo-
sure (upper panel) and a Western blot detection of Raf-1 immuno-
precipitates (lower panel).
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tants signi¢cantly a¡ect p38-MAPK activation as shown by
Western blot detection with phospho-p38 speci¢c antibodies.
Expression levels of p38 and of PKCW were analyzed by West-
ern blot detection (Fig. 2B, middle and lower panel). Activa-
tion of JNK was measured upon transient expression of the
indicated PKCW mutants by in vitro phosphorylation of GST-
jun using JNK immunoprecipitates. As a positive control for
JNK activation cellular stimulation with TNF was performed.
Expression of PKCW was monitored by Western blot analysis
(data not shown). As shown in Fig. 2C no enhancement,
rather weak inhibition of JNK activity by PKCWvPH could
be demonstrated (Fig. 2C). JNK activation was furtheron
measured upon coexpression of PKCW mutants with FLAG-
tagged JNK. FLAG immunoprecipitates did not show signi¢-
cant changes in GST-jun phosphorylation (I.B., unpublished
observations). PKCW mutants used in this study were ana-
lyzed by in vitro kinase assays upon transient expression
(Fig. 2D). The data presented in this study point to a rather
selective role for PKCW in the activation of the p42 MAPK.
3.3. Activation of transcription factors by PKCW
As PKCW activates p42 MAPK cascade, potential down-
stream gene activation was expected. The SRE in the c-fos
promotor is necessary and su⁄cient for growth factor-medi-
Fig. 2. PKCW activates the p42/44 MAPK but not p38 and JNK. A: Constitutive active PKCW activates p42/44 MAPK. HEK293 cells were
transfected with the indicated constructs and subjected to Western blot analysis using either phospho-p42/44 speci¢c antibodies (upper panel)
or p42/p44 antibodies (lower panel) to estimate loads of each lane. B: Activation of the p38 MAPK. Upon transient expression of the indicated
constructs, p38 activation was measured with phospho-p38 speci¢c antibodies (upper panel). The lower panels show Western blot detection of
p38 and PKCW. C: PKCW does not activate JNK activity. HEK293 cells were transfected with the indicated constructs and JNK activation
was measured by in vitro phosphorylation of GST-jun using JNK immunoprecipitates. D: In vitro kinase assay of PKCW expression constructs
used in this study. The indicated PKCW mutants were expressed in HEK293 cells, immunoprecipitated and subjected to in vitro kinase assays
(upper panel). Western blot controls are shown in the lower panel.
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ated transcription. It has been demonstrated previously that
PKCK and PKCO are involved in SRE-mediated transcription
[34]. Therefore we tested whether PKCW similarly activates
SRE-triggered gene expression. A reporter gene construct con-
taining a basal thymidine kinase (Tk) promotor followed by
four SRE recognition sites and a luciferase gene was used
(4USRE-Tk-luc). Wild-type PKCW or PKCW mutants were
coexpressed together with 4USRE-Tk-luc and pCH110 for
Fig. 3. Expression of constitutive active PKCW enhances SRE driven luciferase activity. A: HEK293 cells were transfected with the indicated
expression constructs and either left untreated or stimulated for 6 h with phorbol ester. Luciferase activity was normalized against transfection
rates by measuring L-galactosidase activity (see Section 2). SRE-transfected cells were compared to cells transfected with a Tk-luciferase con-
struct lacking any SRE sites to show speci¢city. B: HEK293 cells were transfected with the indicated constructs and proceeded as in A. Experi-
ments were carried out in the presence of the MEK1 inhibitor PD98059 or upon serum starving as indicated. Relative activation factors of
non-stimulated cells are indicated. C: PKCW speci¢cally activates TCF/Elk-1. pGAL4-luc and pGAL4DB-Elk-1 plasmids were expressed togeth-
er with PKCWvPH and pCH110. This allows monitoring of luciferase activity directly driven by activation of the Gal4-Elk-1 transcriptional acti-
vator.
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normalization of transfection e⁄ciencies. As indicated in Fig.
3A luciferase activity was measured upon PKCW expression in
either non-stimulated or phorbol ester-stimulated cells (see
Section 2). Phorbol ester stimulation of vector-transfected
cells did not lead to a signi¢cant change in luciferase expres-
sion. Expression of PKCW wild-type resulted in a 3-fold en-
hancement of luciferase activity which could be signi¢cantly
ampli¢ed upon phorbol ester stimulation. Expression of the
kinase dead PKCWK612W mutant did not lead to a detectable
change in luciferase expression. In contrast, expression of con-
stitutive active PKCWvPH results in high basal SRE driven
luciferase activity which is una¡ected by phorbol ester treat-
ment (Fig. 3A). As a control for SRE speci¢city PKCW mu-
tants were coexpressed with a Tk-luciferase reporter gene
lacking the serum responsive elements. In all cases only
weak background activity was obtained (Fig. 3A, right col-
umns).
PKCWvPH-enhanced activation of SRE driven luciferase ac-
tivity is dependent on MAPK activation. As shown in Fig. 3B
PKCWvPH-induced luciferase activity could be e¡ectively re-
pressed by preincubation with the MEK1 speci¢c inhibitor
PD98059 (Fig. 3B, middle columns). Activation of SRE driv-
en luciferase could be enhanced upon serum starvation of
transfected cells. In this case expression of constitutive active
PKCWvPH led to a 15-fold enhancement of luciferase activity
independent of phorbol ester stimulation (Fig. 3B, right col-
umns). Similarly, enhancement of PKCWvPH-mediated SRE
driven gene activation was demonstrated in NIH3T3 cells
(data not shown).
The serum responsive element is constitutive occupied by a
protein complex comprising the serum responsive factor and a
ternary complex factor Elk-1 [35]. Phosphorylation of Elk-1
which is the major substrate of p42/44 in mammalian cells
leads to c-fos transcription. To test whether PKCW triggers
Elk-1-mediated gene activation, HEK293 cells were trans-
fected with pGAL4-luc and pGAL4DB-Elk-1 plasmids to-
gether with PKCWvPH and pCH110 for normalization.
pGAL4-luc is a luciferase reporter plasmid containing ¢ve
copies of the GAL4 response element. pGAL4DB-Elk-1 en-
codes a fusion protein consisting of the amino-terminal GAL4
DNA binding domain and a carboxy-terminal Elk-1 transac-
tivation domain. Activation of the Elk-1 transactivation do-
main by phosphorylation activates transcription of the GAL4
driven luciferase gene. As shown in Fig. 3C expression of
PKCWvPH results in 8^10-fold enhancement of GAL4 driven
luciferase activity. Expression of the kinase dead PKCWK612W
mutant almost leads to basal levels of reporter gene activity.
In this study we can show that PKCW is involved in the
mitogenic pathway. Expression of constitutive active PKCW
activates Raf-1 leading to p42 MAPK activation. This in
turn leads to Elk-1 phosphorylation resulting in SRE driven
gene transcription.
Until now the precise function of PKCW/PKD in growth
control is unknown. Growth factor-mediated activation of
PKD is considered to be mediated via PLCQ-generated di-
acylglycerol [14]. Independent studies similarly showed that
PKCW is associated with PLCQ within the activated B cell
receptor complex suggesting a negative regulatory role in
the phosphoinositol metabolism [36]. According to these
data a receptor proximal function of PKCW is predicted lead-
ing to Raf-1 activation. PKD has been reported to be acti-
vated by oxidative stress [37] which also activates p42 MAPK
(I.B., unpublished observations). PKD activation by oxidative
stress is inhibited partially by a PLCQ speci¢c inhibitor which
further underlines the role of PLCQ in PKCW/PKD-triggered
cellular pathways leading to MAPK activation.
Further studies showed that PKCW is activated by PKCs as
upstream kinases identifying the isotypes O and R as most
likely candidates [25]. Especially PKCR seems to be most im-
portant to activate PKCW/PKD as it is physically associated
with PKD [38]. PKCW-induced Raf-1 activation is most likely
not dependent on PKCR. Initial studies coexpressing consti-
tutive active PKCR together with wild-type PKCW in NIH3T3
cells did not lead to enhanced p42/p44 MAPK activation
(I.B., unpublished observations). Further studies to unravel
the precise role of PKCW/PKD in PLCQ-triggered cellular
pathways have to be performed, especially to characterize
pathways leading to Raf-1 activation and downstream tran-
scription factor activation.
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